ArticleBMC microbiology2026
Invasive Streptococcus agalactiae infections in infants in Guangzhou, Southern China (2013-2022): molecular epidemiology and clinical management implications.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Streptococcus agalactiae (group B Streptococcus, GBS) is an important cause of invasive infections in infants worldwide, despite widespread implementation of intrapartum antibiotic prophylaxis (IAP). This study aimed to clarify the molecular and clinical characteristics of invasive GBS isolates from infants in Guangzhou, China, over the 10-year period 2013-2022. A total of 131 GBS strains were recovered from blood cultures (n = 98) and cerebrospinal fluid cultures (n = 33) of infants aged ≤ 90 days. All isolates were subjected to capsular serotyping, multilocus sequence typing (MLST), virulence gene profiling (including cylE, hylB, Alp family genes, and pilus island genes), and antimicrobial susceptibility testing. Of the 131 GBS isolates, 37 (28.2%) caused early-onset disease (EOD) and 94 (71.8%) caused late-onset disease (LOD). The hypervirulent III/ST17 clone was the predominant lineage (56.5%) and was associated with LOD. Serotype Ia accounted for 15.3% of all isolates and was correlated with respiratory distress in EOD cases. All isolates carried the cylE and hylB toxin genes, with rib being the most prevalent surface protein gene (71.8%). Pilus island PI-2b (67.9%) was the dominant type and was predominantly detected in serotype III/CC17 strains. Resistance rates to clindamycin, erythromycin, and tetracycline exceeded 80%, while all isolates remained susceptible to penicillin and ampicillin. This study confirms that the III/ST17 clone is the predominant lineage associated with GBS LOD and identifies an association between serotype Ia and respiratory distress in GBS EOD. These findings support ongoing molecular surveillance to guide targeted preventive strategies and improve clinical management of invasive infantile GBS disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.